181 related articles for article (PubMed ID: 19164241)
1. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
Tolmachev V; Friedman M; Sandström M; Eriksson TL; Rosik D; Hodik M; Ståhl S; Frejd FY; Orlova A
J Nucl Med; 2009 Feb; 50(2):274-83. PubMed ID: 19164241
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.
Andersson KG; Oroujeni M; Garousi J; Mitran B; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Dec; 49(6):2285-2293. PubMed ID: 27748899
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
4. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl ML; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Apr; 48(4):1325-32. PubMed ID: 26847636
[TBL] [Abstract][Full Text] [Related]
6. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
7. Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.
Sandström K; Haylock AK; Velikyan I; Spiegelberg D; Kareem H; Tolmachev V; Lundqvist H; Nestor M
Cancer Biother Radiopharm; 2011 Oct; 26(5):593-601. PubMed ID: 21834651
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.
Su X; Cheng K; Jeon J; Shen B; Venturin GT; Hu X; Rao J; Chin FT; Wu H; Cheng Z
Mol Pharm; 2014 Nov; 11(11):3947-56. PubMed ID: 24972326
[TBL] [Abstract][Full Text] [Related]
9. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.
Nordberg E; Orlova A; Friedman M; Tolmachev V; Ståhl S; Nilsson FY; Glimelius B; Carlsson J
Oncol Rep; 2008 Apr; 19(4):853-7. PubMed ID: 18357367
[TBL] [Abstract][Full Text] [Related]
11. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
[TBL] [Abstract][Full Text] [Related]
13. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
14. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
Velikyan I; Sundberg AL; Lindhe O; Höglund AU; Eriksson O; Werner E; Carlsson J; Bergström M; Långström B; Tolmachev V
J Nucl Med; 2005 Nov; 46(11):1881-8. PubMed ID: 16269603
[TBL] [Abstract][Full Text] [Related]
15. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.
Tolmachev V; Tran TA; Rosik D; Sjöberg A; Abrahmsén L; Orlova A
J Nucl Med; 2012 Jun; 53(6):953-60. PubMed ID: 22586147
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of [
Oroujeni M; Garousi J; Andersson KG; Löfblom J; Mitran B; Orlova A; Tolmachev V
Cells; 2018 Sep; 7(9):. PubMed ID: 30231504
[TBL] [Abstract][Full Text] [Related]
18. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Friedman M; Orlova A; Johansson E; Eriksson TL; Höidén-Guthenberg I; Tolmachev V; Nilsson FY; Ståhl S
J Mol Biol; 2008 Mar; 376(5):1388-402. PubMed ID: 18207161
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
